Mode
Text Size
Log in / Sign up
N/A Completed N=3,366

Post-Marketing Study of the Safety of Prevenar (Pneumococcal Conjugate Vaccine, 7-valent)

Vaccines, Pneumococcal Conjugate Vaccine
Source: ClinicalTrials.gov NCT00683410 ↗
Enrolled (actual)
3,366
Serious AEs
0.1%
Results posted
Nov 2010
Primary outcomePrimary: Number of Participants With Spontaneous Adverse Events — 91 Participants

Summary

To collect post-marketing information on the safety of Prevenar in Filipino patients

Outcome Measures

OutcomeResultp-value
PRIMARY
Number of Participants With Spontaneous Adverse Events
91 —

Eligibility Criteria

Inclusion Criteria

  • All patients from the study center who received or will receive at least one dose of Prevenar according to the approved product indication.

Exclusion Criteria

  • Previously discontinued Prevenar therapy due to safety concerns.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00683410). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search